Uncertainty in the Business Environment Due to COVID-19
First written in FY2022-Q2. 4 of 10 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024DroppedAnnual report
「More than 4 years have passed since the start of the spread of COVID-19. Based on the widespread administration of vaccines, the development and launch of treatments, and the infection situation across society during this period, we determined that the impact and risk of the infection on our business were not material and deleted the section titled “(3) Risks Related to Business Performance, Financial Position and Capital Policy, etc. ⑥ Impact of the Spread of COVID-19” that had been included in the annual securities report for the previous fiscal year.」
The company determined that the business impact and risk of COVID-19 were not material and deleted the risk disclosure included in the previous fiscal year. - FY2024-Q2DroppedAnnual report
「A gradual recovery trend continued, driven by increased personal consumption and inbound demand accompanying the normalization of economic activity, while」
COVID-19 is no longer described as a direct source of uncertainty, and the wording has shifted toward the normalization of economic activity. - FY2024-Q1SoftenedAnnual report
「With the easing of restrictions on activities related to COVID-19, signs of a normalization in economic activity emerged and a gradual recovery continued, but」
The company describes the easing of restrictions on activities and the normalization of economic activity related to COVID-19, representing a shift from its previous references to uncertainty caused by the spread of the infection toward normalization. - FY2023RestatedAnnual report
「There is currently no adverse business impact from the spread of COVID-19. Rather, it has prompted discussion of the digitalization of healthcare and the remote conduct of clinical trials, creating a favorable environment for the company, which aims to develop therapeutic applications and improve the efficiency of clinical trials.」
The company continues to explain that the spread of COVID-19 has had no adverse business impact and that the digitalization of healthcare and related developments have created a favorable environment. - FY2023-Q3RestatedAnnual report
「As of the present time, the impact of COVID-19 and the geopolitical risks related to the situation in Ukraine on the company's performance is limited.」
The impact of COVID-19 and the geopolitical risks related to the situation in Ukraine on the company's performance continues to be described as limited. - FY2023-Q2RestatedAnnual report
「As of the present time, the impact of COVID-19 and the geopolitical risks related to the situation in Ukraine on the company's performance is limited.」
The company continues to explain that the impact of COVID-19 on its performance is limited. - FY2023-Q1RestatedAnnual report
「As of the present time, the impact of COVID-19 and the geopolitical risks related to the situation in Ukraine on the company's performance is limited.」
The company continues to explain that the impact of COVID-19 on its performance is limited. - FY2022SoftenedAnnual report
「There is currently no adverse business impact from the spread of COVID-19. Rather, it has prompted discussion of the digitalization of healthcare and the remote conduct of clinical trials, creating a favorable environment for the company, which aims to develop therapeutic applications and improve the efficiency of clinical trials.」
Although uncertainty surrounding the spread of the infection remains, the company explains that there was no adverse business impact during the fiscal year and that the environment was rather favorable. - FY2022-Q3WorsenedAnnual report
「The outlook remains uncertain due to the spread of new variants and geopolitical risks related to the situation in Ukraine. As of the present time, however, the impact of COVID-19 and the geopolitical risks related to the situation in Ukraine on the company's performance is limited.」
In addition to COVID-19, geopolitical risks related to the situation in Ukraine became an additional source of uncertainty. However, the company explains that the impact on its performance was limited as of the filing date. - FY2022-Q2First statedAnnual report
「The outlook remains uncertain as social and economic activity has been restricted due to the spread of COVID-19. As of the present time, however, the impact of COVID-19 on the company's performance is limited.」
Although uncertainty in the external environment continues, the company explains that the impact on its performance was limited as of the filing date.